A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 17 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 21 Jun 2016 Status changed from recruiting to active, no longer recruiting.